[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnPRdffuRAAmfHO7mVz7F9Odme_kyUv0cCB84M2f-5kk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"Heinrich-Heine University, Duesseldorf",[4],175,false,48,4,55243,9,141,[14,17,19,22,24,27,29,31],{"name":15,"count":16},"Schizophrenia",8,{"name":18,"count":16},"Prostate Cancer",{"name":20,"count":21},"Cardiovascular Diseases",5,{"name":23,"count":9},"Multiple Sclerosis",{"name":25,"count":26},"Healthy",3,{"name":28,"count":26},"Acute Kidney Injury",{"name":30,"count":26},"Critical Illness",{"name":32,"count":26},"Heart Transplantation",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05807932","Venetoclax in Addition to Sequential Conditioning With Fludarabine \u002F Amsacrine \u002F Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","2026-01-31","Venetoclax",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06144736","PRIMETEST II - Clinical Stage II A\u002FB Seminoma Treated With RA-RPLND","2026-08-31","Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03395587","Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma","2027-05","Autologous, tumor lysate-loaded, mature dendritic cells",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06586177","Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies","2028-12-31","Anti-CD20 antibody",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,87,110,128,156,174,192,210,228,249,291,318,336,363,381,399,424,448,473,497,522,540,566,584,609,637,669,687,705,723,741,759,777,795,835,861,887,913,937,963,988,1006,1029,1047,1065,1089,1114,1132,1150,1174,1200,1223,1249,1277,1306,1324,1342,1360,1378],{"intervention":43,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":81,"PHASE4":83,"NA":85},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":63,"soonestReadout":42},[72],{"nctId":40,"briefTitle":41,"status":73,"phases":74,"primaryCompletion":42,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":80},"RECRUITING",[57],"2029-08-31","2023-08-28",60,[79],"Seminoma",[43],{"trials":82,"activeCount":67},[],{"trials":84,"activeCount":67},[],{"trials":86,"activeCount":67},[],{"intervention":48,"totalTrials":63,"cells":88},{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":90,"activeCount":67},[],{"trials":92,"activeCount":67},[],{"trials":94,"activeCount":63,"soonestReadout":47},[95],{"nctId":45,"briefTitle":46,"status":96,"phases":97,"primaryCompletion":47,"completion":47,"start":98,"enrollment":99,"conditions":100,"interventions":102},"ACTIVE_NOT_RECRUITING",[57],"2018-03-06",136,[101],"Glioblastoma",[48,103],"standard therapy",{"trials":105,"activeCount":67},[],{"trials":107,"activeCount":67},[],{"trials":109,"activeCount":67},[],{"intervention":103,"totalTrials":63,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":122,"PHASE4":124,"NA":126},{"trials":113,"activeCount":67},[],{"trials":115,"activeCount":67},[],{"trials":117,"activeCount":63,"soonestReadout":47},[118],{"nctId":45,"briefTitle":46,"status":96,"phases":119,"primaryCompletion":47,"completion":47,"start":98,"enrollment":99,"conditions":120,"interventions":121},[57],[101],[48,103],{"trials":123,"activeCount":67},[],{"trials":125,"activeCount":67},[],{"trials":127,"activeCount":67},[],{"intervention":38,"totalTrials":63,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":131,"activeCount":67},[],{"trials":133,"activeCount":67},[],{"trials":135,"activeCount":63,"soonestReadout":37},[136],{"nctId":35,"briefTitle":36,"status":73,"phases":137,"primaryCompletion":37,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":145},[56,57],"2028-01-30","2023-06-26",38,[142,143,144],"Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia",[38,146,147,148,149],"Amsacrine","Ara-C","Tacrolimus","Mycophenolate Mofetil",{"trials":151,"activeCount":67},[],{"trials":153,"activeCount":67},[],{"trials":155,"activeCount":67},[],{"intervention":146,"totalTrials":63,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":159,"activeCount":67},[],{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":63,"soonestReadout":37},[164],{"nctId":35,"briefTitle":36,"status":73,"phases":165,"primaryCompletion":37,"completion":138,"start":139,"enrollment":140,"conditions":166,"interventions":167},[56,57],[142,143,144],[38,146,147,148,149],{"trials":169,"activeCount":67},[],{"trials":171,"activeCount":67},[],{"trials":173,"activeCount":67},[],{"intervention":147,"totalTrials":63,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":186,"PHASE4":188,"NA":190},{"trials":177,"activeCount":67},[],{"trials":179,"activeCount":67},[],{"trials":181,"activeCount":63,"soonestReadout":37},[182],{"nctId":35,"briefTitle":36,"status":73,"phases":183,"primaryCompletion":37,"completion":138,"start":139,"enrollment":140,"conditions":184,"interventions":185},[56,57],[142,143,144],[38,146,147,148,149],{"trials":187,"activeCount":67},[],{"trials":189,"activeCount":67},[],{"trials":191,"activeCount":67},[],{"intervention":148,"totalTrials":63,"cells":193},{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":204,"PHASE4":206,"NA":208},{"trials":195,"activeCount":67},[],{"trials":197,"activeCount":67},[],{"trials":199,"activeCount":63,"soonestReadout":37},[200],{"nctId":35,"briefTitle":36,"status":73,"phases":201,"primaryCompletion":37,"completion":138,"start":139,"enrollment":140,"conditions":202,"interventions":203},[56,57],[142,143,144],[38,146,147,148,149],{"trials":205,"activeCount":67},[],{"trials":207,"activeCount":67},[],{"trials":209,"activeCount":67},[],{"intervention":149,"totalTrials":63,"cells":211},{"EARLY_PHASE1":212,"PHASE1":214,"PHASE2":216,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":213,"activeCount":67},[],{"trials":215,"activeCount":67},[],{"trials":217,"activeCount":63,"soonestReadout":37},[218],{"nctId":35,"briefTitle":36,"status":73,"phases":219,"primaryCompletion":37,"completion":138,"start":139,"enrollment":140,"conditions":220,"interventions":221},[56,57],[142,143,144],[38,146,147,148,149],{"trials":223,"activeCount":67},[],{"trials":225,"activeCount":67},[],{"trials":227,"activeCount":67},[],{"intervention":53,"totalTrials":63,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":236,"PHASE4":238,"NA":240},{"trials":231,"activeCount":67},[],{"trials":233,"activeCount":67},[],{"trials":235,"activeCount":67},[],{"trials":237,"activeCount":67},[],{"trials":239,"activeCount":67},[],{"trials":241,"activeCount":63,"soonestReadout":52},[242],{"nctId":50,"briefTitle":51,"status":73,"phases":243,"primaryCompletion":52,"completion":52,"start":244,"enrollment":245,"conditions":246,"interventions":248},[],"2021-10-27",100,[247],"Relapsing-remitting Multiple Sclerosis",[53],{"intervention":250,"totalTrials":251,"cells":252},"Camostat Mesilate",2,{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":274,"PHASE4":276,"NA":289},{"trials":254,"activeCount":67},[],{"trials":256,"activeCount":67},[],{"trials":258,"activeCount":67},[259],{"nctId":260,"briefTitle":261,"status":262,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":272},"NCT04681430","Reconvalescent Plasma\u002FCamostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals","COMPLETED",[57],"2021-10-29","2021-01-08",22,[268,269,270,271],"Corona Virus Infection","SARS-CoV-2 Infection","SARS-CoV-2 PCR Test Positive","SARS-CoV-2 Acute Respiratory Disease",[273,250],"Convalescent plasma",{"trials":275,"activeCount":67},[],{"trials":277,"activeCount":67},[278],{"nctId":279,"briefTitle":280,"status":281,"phases":282,"primaryCompletion":283,"completion":283,"start":284,"enrollment":67,"conditions":285,"interventions":287},"NCT04338906","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","WITHDRAWN",[59],"2021-12","2020-05",[286],"COVID",[250,288],"Hydroxychloroquine",{"trials":290,"activeCount":67},[],{"intervention":292,"totalTrials":63,"cells":293},"Argatroban",{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":316},{"trials":295,"activeCount":67},[],{"trials":297,"activeCount":67},[],{"trials":299,"activeCount":67},[],{"trials":301,"activeCount":67},[],{"trials":303,"activeCount":67},[304],{"nctId":305,"briefTitle":306,"status":307,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":314},"NCT00798525","Argatroban Versus Lepirudin in Critically Ill Patients","TERMINATED",[59],"2012-03","2009-01",70,[313],"Heparin Induced Thrombocytopenia (HIT)",[292,315],"Lepirudin",{"trials":317,"activeCount":67},[],{"intervention":315,"totalTrials":63,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":334},{"trials":321,"activeCount":67},[],{"trials":323,"activeCount":67},[],{"trials":325,"activeCount":67},[],{"trials":327,"activeCount":67},[],{"trials":329,"activeCount":67},[330],{"nctId":305,"briefTitle":306,"status":307,"phases":331,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":332,"interventions":333},[59],[313],[292,315],{"trials":335,"activeCount":67},[],{"intervention":337,"totalTrials":63,"cells":338},"Olanzapine",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":361},{"trials":340,"activeCount":67},[],{"trials":342,"activeCount":67},[],{"trials":344,"activeCount":67},[],{"trials":346,"activeCount":67},[],{"trials":348,"activeCount":67},[349],{"nctId":350,"briefTitle":351,"status":262,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":358},"NCT01609153","Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy",[59],"2019-04","2012-06",328,[15,357],"Schizoaffective Disorder",[337,359,360],"Amisulpride","Olanzapine and Amisulpride",{"trials":362,"activeCount":67},[],{"intervention":359,"totalTrials":63,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":379},{"trials":366,"activeCount":67},[],{"trials":368,"activeCount":67},[],{"trials":370,"activeCount":67},[],{"trials":372,"activeCount":67},[],{"trials":374,"activeCount":67},[375],{"nctId":350,"briefTitle":351,"status":262,"phases":376,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":377,"interventions":378},[59],[15,357],[337,359,360],{"trials":380,"activeCount":67},[],{"intervention":360,"totalTrials":63,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":397},{"trials":384,"activeCount":67},[],{"trials":386,"activeCount":67},[],{"trials":388,"activeCount":67},[],{"trials":390,"activeCount":67},[],{"trials":392,"activeCount":67},[393],{"nctId":350,"briefTitle":351,"status":262,"phases":394,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":395,"interventions":396},[59],[15,357],[337,359,360],{"trials":398,"activeCount":67},[],{"intervention":400,"totalTrials":63,"cells":401},"Fingolimod",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":422},{"trials":403,"activeCount":67},[],{"trials":405,"activeCount":67},[],{"trials":407,"activeCount":67},[],{"trials":409,"activeCount":67},[],{"trials":411,"activeCount":67},[412],{"nctId":413,"briefTitle":414,"status":307,"phases":415,"primaryCompletion":416,"completion":417,"start":418,"enrollment":16,"conditions":419,"interventions":421},"NCT01755871","Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis",[59],"2016-01","2016-02","2013-01",[420],"Relapsing Remitting Multiple Sclerosis",[400],{"trials":423,"activeCount":67},[],{"intervention":425,"totalTrials":63,"cells":426},"Haloperidol, Risperidone",{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":446},{"trials":428,"activeCount":67},[],{"trials":430,"activeCount":67},[],{"trials":432,"activeCount":67},[],{"trials":434,"activeCount":67},[],{"trials":436,"activeCount":67},[437],{"nctId":438,"briefTitle":439,"status":262,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":445},"NCT00159081","One Year Drug Treatment in First-Episode Schizophrenia",[59],"2005-06","2000-11",159,[15],[425],{"trials":447,"activeCount":67},[],{"intervention":449,"totalTrials":63,"cells":450},"Acamprosate",{"EARLY_PHASE1":451,"PHASE1":453,"PHASE2":455,"PHASE3":457,"PHASE4":459,"NA":471},{"trials":452,"activeCount":67},[],{"trials":454,"activeCount":67},[],{"trials":456,"activeCount":67},[],{"trials":458,"activeCount":67},[],{"trials":460,"activeCount":67},[461],{"nctId":462,"briefTitle":463,"status":262,"phases":464,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":470},"NCT00159107","Integrative Therapy in Alcoholism",[59],"2006-12","2003-05",371,[469],"Alcoholism",[449],{"trials":472,"activeCount":67},[],{"intervention":474,"totalTrials":63,"cells":475},"Xenon",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":495},{"trials":477,"activeCount":67},[],{"trials":479,"activeCount":67},[],{"trials":481,"activeCount":67},[],{"trials":483,"activeCount":67},[],{"trials":485,"activeCount":67},[486],{"nctId":487,"briefTitle":488,"status":262,"phases":489,"primaryCompletion":490,"completion":490,"start":417,"enrollment":491,"conditions":492,"interventions":494},"NCT02682758","Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution",[59],"2016-03",20,[493],"Anesthesia",[474],{"trials":496,"activeCount":67},[],{"intervention":498,"totalTrials":63,"cells":499},"antipsychotics vs. Lorazepam",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":520},{"trials":501,"activeCount":67},[],{"trials":503,"activeCount":67},[],{"trials":505,"activeCount":67},[],{"trials":507,"activeCount":67},[],{"trials":509,"activeCount":67},[510],{"nctId":511,"briefTitle":512,"status":262,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT00159133","Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia",[59],"2006-06","2001-11",71,[15,518],"Psychoses",[498],{"trials":521,"activeCount":67},[],{"intervention":288,"totalTrials":63,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":532,"NA":538},{"trials":525,"activeCount":67},[],{"trials":527,"activeCount":67},[],{"trials":529,"activeCount":67},[],{"trials":531,"activeCount":67},[],{"trials":533,"activeCount":67},[534],{"nctId":279,"briefTitle":280,"status":281,"phases":535,"primaryCompletion":283,"completion":283,"start":284,"enrollment":67,"conditions":536,"interventions":537},[59],[286],[250,288],{"trials":539,"activeCount":67},[],{"intervention":541,"totalTrials":63,"cells":542},"DTaP-IPV-HBV\u002FHib combination vaccine, Infanrix hexa",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":562,"NA":564},{"trials":544,"activeCount":67},[],{"trials":546,"activeCount":67},[],{"trials":548,"activeCount":67},[],{"trials":550,"activeCount":67},[551],{"nctId":552,"briefTitle":553,"status":262,"phases":554,"primaryCompletion":514,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":560},"NCT00169728","Vaccination of Children Following Allogeneic Stem Cell Transplantation",[58],"2006-10","2003-09",53,[559],"Allogeneic Haematopoietic Stem Cell Transplantation",[541,561],"heptavalent pneumococcal conjugate vaccine, Prevenar",{"trials":563,"activeCount":67},[],{"trials":565,"activeCount":67},[],{"intervention":561,"totalTrials":63,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":580,"NA":582},{"trials":569,"activeCount":67},[],{"trials":571,"activeCount":67},[],{"trials":573,"activeCount":67},[],{"trials":575,"activeCount":67},[576],{"nctId":552,"briefTitle":553,"status":262,"phases":577,"primaryCompletion":514,"completion":555,"start":556,"enrollment":557,"conditions":578,"interventions":579},[58],[559],[541,561],{"trials":581,"activeCount":67},[],{"trials":583,"activeCount":67},[],{"intervention":585,"totalTrials":63,"cells":586},"Adalimumab",{"EARLY_PHASE1":587,"PHASE1":589,"PHASE2":591,"PHASE3":593,"PHASE4":605,"NA":607},{"trials":588,"activeCount":67},[],{"trials":590,"activeCount":67},[],{"trials":592,"activeCount":67},[],{"trials":594,"activeCount":67},[595],{"nctId":596,"briefTitle":597,"status":307,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":604},"NCT02150473","The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients",[58],"2017-09-14","2014-10",21,[603],"Rheumatoid Arthritis",[585],{"trials":606,"activeCount":67},[],{"trials":608,"activeCount":67},[],{"intervention":610,"totalTrials":63,"cells":611},"sunscreen RV 2547C",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":633,"NA":635},{"trials":613,"activeCount":67},[],{"trials":615,"activeCount":67},[],{"trials":617,"activeCount":67},[],{"trials":619,"activeCount":67},[620],{"nctId":621,"briefTitle":622,"status":262,"phases":623,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":632},"NCT00470912","Sunscreen RV 2457C in Photoinduced CLE",[58],"2002-02","2001-05",25,[628,629,630,631],"Cutaneous Lupus Erythematosus","Skin Lesion","Experimental Photoinduction","Protective Sunscreen",[610],{"trials":634,"activeCount":67},[],{"trials":636,"activeCount":67},[],{"intervention":638,"totalTrials":63,"cells":639},"Trimethoprim-Sulfamethoxazole",{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":665,"NA":667},{"trials":641,"activeCount":67},[],{"trials":643,"activeCount":67},[],{"trials":645,"activeCount":67},[],{"trials":647,"activeCount":67},[648],{"nctId":649,"briefTitle":650,"status":262,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT01792804","Staphylococcus Aureus Bacteremia Antibiotic Treatment Options",[58],"2020-03-26","2013-12",215,[656],"Staphylococcus Aureus Infection",[638,658,659,660,661,662,663,664],"Clindamycin","Linezolid","Flucloxacillin","Cloxacillin","Vancomycin","Daptomycin","Cefazolin",{"trials":666,"activeCount":67},[],{"trials":668,"activeCount":67},[],{"intervention":658,"totalTrials":63,"cells":670},{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":683,"NA":685},{"trials":672,"activeCount":67},[],{"trials":674,"activeCount":67},[],{"trials":676,"activeCount":67},[],{"trials":678,"activeCount":67},[679],{"nctId":649,"briefTitle":650,"status":262,"phases":680,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":681,"interventions":682},[58],[656],[638,658,659,660,661,662,663,664],{"trials":684,"activeCount":67},[],{"trials":686,"activeCount":67},[],{"intervention":659,"totalTrials":63,"cells":688},{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":695,"PHASE4":701,"NA":703},{"trials":690,"activeCount":67},[],{"trials":692,"activeCount":67},[],{"trials":694,"activeCount":67},[],{"trials":696,"activeCount":67},[697],{"nctId":649,"briefTitle":650,"status":262,"phases":698,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":699,"interventions":700},[58],[656],[638,658,659,660,661,662,663,664],{"trials":702,"activeCount":67},[],{"trials":704,"activeCount":67},[],{"intervention":660,"totalTrials":63,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":721},{"trials":708,"activeCount":67},[],{"trials":710,"activeCount":67},[],{"trials":712,"activeCount":67},[],{"trials":714,"activeCount":67},[715],{"nctId":649,"briefTitle":650,"status":262,"phases":716,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":717,"interventions":718},[58],[656],[638,658,659,660,661,662,663,664],{"trials":720,"activeCount":67},[],{"trials":722,"activeCount":67},[],{"intervention":661,"totalTrials":63,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":737,"NA":739},{"trials":726,"activeCount":67},[],{"trials":728,"activeCount":67},[],{"trials":730,"activeCount":67},[],{"trials":732,"activeCount":67},[733],{"nctId":649,"briefTitle":650,"status":262,"phases":734,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":735,"interventions":736},[58],[656],[638,658,659,660,661,662,663,664],{"trials":738,"activeCount":67},[],{"trials":740,"activeCount":67},[],{"intervention":662,"totalTrials":63,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":755,"NA":757},{"trials":744,"activeCount":67},[],{"trials":746,"activeCount":67},[],{"trials":748,"activeCount":67},[],{"trials":750,"activeCount":67},[751],{"nctId":649,"briefTitle":650,"status":262,"phases":752,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":753,"interventions":754},[58],[656],[638,658,659,660,661,662,663,664],{"trials":756,"activeCount":67},[],{"trials":758,"activeCount":67},[],{"intervention":663,"totalTrials":63,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":773,"NA":775},{"trials":762,"activeCount":67},[],{"trials":764,"activeCount":67},[],{"trials":766,"activeCount":67},[],{"trials":768,"activeCount":67},[769],{"nctId":649,"briefTitle":650,"status":262,"phases":770,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":771,"interventions":772},[58],[656],[638,658,659,660,661,662,663,664],{"trials":774,"activeCount":67},[],{"trials":776,"activeCount":67},[],{"intervention":664,"totalTrials":63,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":791,"NA":793},{"trials":780,"activeCount":67},[],{"trials":782,"activeCount":67},[],{"trials":784,"activeCount":67},[],{"trials":786,"activeCount":67},[787],{"nctId":649,"briefTitle":650,"status":262,"phases":788,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":789,"interventions":790},[58],[656],[638,658,659,660,661,662,663,664],{"trials":792,"activeCount":67},[],{"trials":794,"activeCount":67},[],{"intervention":796,"totalTrials":251,"cells":797},"Lenalidomide",{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":799,"activeCount":67},[],{"trials":801,"activeCount":67},[],{"trials":803,"activeCount":67},[804,816],{"nctId":805,"briefTitle":806,"status":307,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":814},"NCT00977132","Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome",[57],"2013-05","2014-05","2009-10",23,[813],"Myelodysplastic Syndrome MDS",[815,796],"Valproic aicd",{"nctId":817,"briefTitle":818,"status":262,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":826},"NCT02472691","Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT",[57],"2020-04-23","2015-05",50,[824,142,825],"Leukemia, Myeloid, Acute","Leukemia, Myelomonocytic, Chronic",[796,827,828],"Azacitidine","Donor Lymphocyte Infusions",{"trials":830,"activeCount":67},[],{"trials":832,"activeCount":67},[],{"trials":834,"activeCount":67},[],{"intervention":836,"totalTrials":63,"cells":837},"Sorafenib",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":842,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":839,"activeCount":67},[],{"trials":841,"activeCount":67},[],{"trials":843,"activeCount":67},[844],{"nctId":845,"briefTitle":846,"status":307,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":854},"NCT00618384","TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)",[57],"2011-05","2011-08","2008-01",43,[853],"Hepatocellular Carcinoma",[836],{"trials":856,"activeCount":67},[],{"trials":858,"activeCount":67},[],{"trials":860,"activeCount":67},[],{"intervention":862,"totalTrials":63,"cells":863},"5-Azacitidine",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":881,"PHASE4":883,"NA":885},{"trials":865,"activeCount":67},[],{"trials":867,"activeCount":67},[],{"trials":869,"activeCount":67},[870],{"nctId":871,"briefTitle":872,"status":262,"phases":873,"primaryCompletion":874,"completion":849,"start":875,"enrollment":876,"conditions":877,"interventions":880},"NCT00795548","Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation",[57],"2010-10","2008-11",30,[878,879],"Myelodysplastic Syndrome","Acute Myeloid Leukemia",[862],{"trials":882,"activeCount":67},[],{"trials":884,"activeCount":67},[],{"trials":886,"activeCount":67},[],{"intervention":888,"totalTrials":63,"cells":889},"Cetuximab",{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":907,"PHASE4":909,"NA":911},{"trials":891,"activeCount":67},[],{"trials":893,"activeCount":67},[],{"trials":895,"activeCount":67},[896],{"nctId":897,"briefTitle":898,"status":262,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":906},"NCT00791141","Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer",[57],"2013-04","2013-09","2008-08",80,[905],"Head and Neck Cancer",[888],{"trials":908,"activeCount":67},[],{"trials":910,"activeCount":67},[],{"trials":912,"activeCount":67},[],{"intervention":914,"totalTrials":63,"cells":915},"Haemate HS",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":917,"activeCount":67},[],{"trials":919,"activeCount":67},[],{"trials":921,"activeCount":67},[922],{"nctId":923,"briefTitle":924,"status":281,"phases":925,"primaryCompletion":926,"completion":927,"start":850,"enrollment":67,"conditions":928,"interventions":930},"NCT00618293","Haemate HS in Patients With Severe Bleeding Undergoing Valve Replacement Due to Aortic Stenosis",[57],"2010-07","2011-07",[929],"Blood Loss, Surgical",[914],{"trials":932,"activeCount":67},[],{"trials":934,"activeCount":67},[],{"trials":936,"activeCount":67},[],{"intervention":938,"totalTrials":63,"cells":939},"Bosentan",{"EARLY_PHASE1":940,"PHASE1":942,"PHASE2":944,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":941,"activeCount":67},[],{"trials":943,"activeCount":67},[],{"trials":945,"activeCount":67},[946],{"nctId":947,"briefTitle":948,"status":262,"phases":949,"completion":950,"start":514,"enrollment":951,"conditions":952,"interventions":956},"NCT00318175","Effect of Bosentan on Skin Fibrosis in Patients With Systemic Sclerosis",[57],"2007-05",10,[953,954,955],"Systemic Scleroderma","Skin Fibrosis","Hand Functionality",[938],{"trials":958,"activeCount":67},[],{"trials":960,"activeCount":67},[],{"trials":962,"activeCount":67},[],{"intervention":964,"totalTrials":63,"cells":965},"paclitaxel",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":967,"activeCount":67},[],{"trials":969,"activeCount":67},[],{"trials":971,"activeCount":67},[972],{"nctId":973,"briefTitle":974,"status":307,"phases":975,"primaryCompletion":418,"completion":901,"start":976,"enrollment":977,"conditions":978,"interventions":980},"NCT00933374","Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma",[57],"2009-07",28,[979],"Bladder Cancer",[964,981],"RAD001",{"trials":983,"activeCount":67},[],{"trials":985,"activeCount":67},[],{"trials":987,"activeCount":67},[],{"intervention":981,"totalTrials":63,"cells":989},{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1000,"PHASE4":1002,"NA":1004},{"trials":991,"activeCount":67},[],{"trials":993,"activeCount":67},[],{"trials":995,"activeCount":67},[996],{"nctId":973,"briefTitle":974,"status":307,"phases":997,"primaryCompletion":418,"completion":901,"start":976,"enrollment":977,"conditions":998,"interventions":999},[57],[979],[964,981],{"trials":1001,"activeCount":67},[],{"trials":1003,"activeCount":67},[],{"trials":1005,"activeCount":67},[],{"intervention":1007,"totalTrials":63,"cells":1008},"Tacrolimus ointment",{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1010,"activeCount":67},[],{"trials":1012,"activeCount":67},[],{"trials":1014,"activeCount":67},[1015],{"nctId":1016,"briefTitle":1017,"status":262,"phases":1018,"completion":1019,"start":1020,"enrollment":876,"conditions":1021,"interventions":1022},"NCT00317681","Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)",[57],"2007-02","2005-08",[628],[1007],{"trials":1024,"activeCount":67},[],{"trials":1026,"activeCount":67},[],{"trials":1028,"activeCount":67},[],{"intervention":815,"totalTrials":63,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1032,"activeCount":67},[],{"trials":1034,"activeCount":67},[],{"trials":1036,"activeCount":67},[1037],{"nctId":805,"briefTitle":806,"status":307,"phases":1038,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":1039,"interventions":1040},[57],[813],[815,796],{"trials":1042,"activeCount":67},[],{"trials":1044,"activeCount":67},[],{"trials":1046,"activeCount":67},[],{"intervention":273,"totalTrials":63,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1050,"activeCount":67},[],{"trials":1052,"activeCount":67},[],{"trials":1054,"activeCount":67},[1055],{"nctId":260,"briefTitle":261,"status":262,"phases":1056,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":1057,"interventions":1058},[57],[268,269,270,271],[273,250],{"trials":1060,"activeCount":67},[],{"trials":1062,"activeCount":67},[],{"trials":1064,"activeCount":67},[],{"intervention":1066,"totalTrials":63,"cells":1067},"Combination of Lonsurf® and Irinotecan",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1069,"activeCount":67},[],{"trials":1071,"activeCount":67},[],{"trials":1073,"activeCount":67},[1074],{"nctId":1075,"briefTitle":1076,"status":262,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":977,"conditions":1080,"interventions":1082},"NCT04059562","Trifluridine\u002FTipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma",[57],"2024-01-08","2021-10-28",[1081],"Cholangiocarcinoma",[1066],{"trials":1084,"activeCount":67},[],{"trials":1086,"activeCount":67},[],{"trials":1088,"activeCount":67},[],{"intervention":1090,"totalTrials":63,"cells":1091},"nicotine nasal spray",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1093,"activeCount":67},[],{"trials":1095,"activeCount":67},[],{"trials":1097,"activeCount":67},[1098],{"nctId":1099,"briefTitle":1100,"status":262,"phases":1101,"primaryCompletion":1102,"completion":1103,"start":850,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT00618280","Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail",[56,57],"2010-06","2010-08",101,[1106,15],"Tobacco Use Disorder",[1090],{"trials":1109,"activeCount":67},[],{"trials":1111,"activeCount":67},[],{"trials":1113,"activeCount":67},[],{"intervention":827,"totalTrials":63,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1117,"activeCount":67},[],{"trials":1119,"activeCount":67},[],{"trials":1121,"activeCount":67},[1122],{"nctId":817,"briefTitle":818,"status":262,"phases":1123,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":1124,"interventions":1125},[57],[824,142,825],[796,827,828],{"trials":1127,"activeCount":67},[],{"trials":1129,"activeCount":67},[],{"trials":1131,"activeCount":67},[],{"intervention":828,"totalTrials":63,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1135,"activeCount":67},[],{"trials":1137,"activeCount":67},[],{"trials":1139,"activeCount":67},[1140],{"nctId":817,"briefTitle":818,"status":262,"phases":1141,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":1142,"interventions":1143},[57],[824,142,825],[796,827,828],{"trials":1145,"activeCount":67},[],{"trials":1147,"activeCount":67},[],{"trials":1149,"activeCount":67},[],{"intervention":1151,"totalTrials":63,"cells":1152},"Brimonidine Tartrate",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1154,"activeCount":67},[],{"trials":1156,"activeCount":67},[],{"trials":1158,"activeCount":67},[1159],{"nctId":1160,"briefTitle":1161,"status":307,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":251,"conditions":1165,"interventions":1167},"NCT03173365","The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients",[57],"2018-12-31","2017-07-10",[1166],"Hand-foot Syndrome",[1151],{"trials":1169,"activeCount":67},[],{"trials":1171,"activeCount":67},[],{"trials":1173,"activeCount":67},[],{"intervention":1175,"totalTrials":63,"cells":1176},"Enasidenib",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1178,"activeCount":67},[],{"trials":1180,"activeCount":67},[],{"trials":1182,"activeCount":67},[1183],{"nctId":1184,"briefTitle":1185,"status":262,"phases":1186,"primaryCompletion":1187,"completion":1187,"start":1188,"enrollment":822,"conditions":1189,"interventions":1193},"NCT04522895","IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT",[57],"2024-07-24","2020-08-27",[824,142,144,1190,1191,1192],"IDH2 Gene Mutation","IDH2 R172","IDH2 R140",[1175],{"trials":1195,"activeCount":67},[],{"trials":1197,"activeCount":67},[],{"trials":1199,"activeCount":67},[],{"intervention":1201,"totalTrials":63,"cells":1202},"Anesthesia with inhalative application of xenon gas",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1211,"NA":1213},{"trials":1204,"activeCount":67},[],{"trials":1206,"activeCount":67},[],{"trials":1208,"activeCount":67},[],{"trials":1210,"activeCount":67},[],{"trials":1212,"activeCount":67},[],{"trials":1214,"activeCount":67},[1215],{"nctId":1216,"briefTitle":1217,"status":262,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":16,"conditions":1221,"interventions":1222},"NCT02105077","Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans",[],"2014-12","2014-03",[493],[1201],{"intervention":1224,"totalTrials":63,"cells":1225},"Flavanol",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1232,"PHASE4":1234,"NA":1236},{"trials":1227,"activeCount":67},[],{"trials":1229,"activeCount":67},[],{"trials":1231,"activeCount":67},[],{"trials":1233,"activeCount":67},[],{"trials":1235,"activeCount":67},[],{"trials":1237,"activeCount":67},[1238],{"nctId":1239,"briefTitle":1240,"status":262,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1248},"NCT05782309","Healthy Aging Through Dietary Intervention",[60],"2022-09-30","2023-02-05","2019-04-01",68,[1247],"Aging, Healthy",[1224],{"intervention":1250,"totalTrials":63,"cells":1251},"Most recent vaccine to seasonal influenza",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1253,"activeCount":67},[],{"trials":1255,"activeCount":67},[],{"trials":1257,"activeCount":67},[],{"trials":1259,"activeCount":67},[],{"trials":1261,"activeCount":67},[],{"trials":1263,"activeCount":67},[1264],{"nctId":1265,"briefTitle":1266,"status":1267,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1276},"NCT05019248","Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","UNKNOWN",[],"2021-12-31","2022-04-30","2020-09-01",260,[1274,1275],"Multiple Sclerosis, Relapsing-Remitting","Vaccine Response Impaired",[1250],{"intervention":1278,"totalTrials":63,"cells":1279},"darbepoetin alfa",{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1284,"PHASE3":1286,"PHASE4":1288,"NA":1290},{"trials":1281,"activeCount":67},[],{"trials":1283,"activeCount":67},[],{"trials":1285,"activeCount":67},[],{"trials":1287,"activeCount":67},[],{"trials":1289,"activeCount":67},[],{"trials":1291,"activeCount":67},[1292],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1300},"NCT00309920","Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer",[60],"2004-01",1234,[1299],"Breast Cancer",[1278,1301,1302,1303,1304,1305],"cyclophosphamide","docetaxel","doxorubicin hydrochloride","epirubicin hydrochloride","fluorouracil",{"intervention":1301,"totalTrials":63,"cells":1307},{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1309,"activeCount":67},[],{"trials":1311,"activeCount":67},[],{"trials":1313,"activeCount":67},[],{"trials":1315,"activeCount":67},[],{"trials":1317,"activeCount":67},[],{"trials":1319,"activeCount":67},[1320],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1321,"start":1296,"enrollment":1297,"conditions":1322,"interventions":1323},[60],[1299],[1278,1301,1302,1303,1304,1305],{"intervention":1302,"totalTrials":63,"cells":1325},{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1327,"activeCount":67},[],{"trials":1329,"activeCount":67},[],{"trials":1331,"activeCount":67},[],{"trials":1333,"activeCount":67},[],{"trials":1335,"activeCount":67},[],{"trials":1337,"activeCount":67},[1338],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1339,"start":1296,"enrollment":1297,"conditions":1340,"interventions":1341},[60],[1299],[1278,1301,1302,1303,1304,1305],{"intervention":1303,"totalTrials":63,"cells":1343},{"EARLY_PHASE1":1344,"PHASE1":1346,"PHASE2":1348,"PHASE3":1350,"PHASE4":1352,"NA":1354},{"trials":1345,"activeCount":67},[],{"trials":1347,"activeCount":67},[],{"trials":1349,"activeCount":67},[],{"trials":1351,"activeCount":67},[],{"trials":1353,"activeCount":67},[],{"trials":1355,"activeCount":67},[1356],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1357,"start":1296,"enrollment":1297,"conditions":1358,"interventions":1359},[60],[1299],[1278,1301,1302,1303,1304,1305],{"intervention":1304,"totalTrials":63,"cells":1361},{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1363,"activeCount":67},[],{"trials":1365,"activeCount":67},[],{"trials":1367,"activeCount":67},[],{"trials":1369,"activeCount":67},[],{"trials":1371,"activeCount":67},[],{"trials":1373,"activeCount":67},[1374],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1375,"start":1296,"enrollment":1297,"conditions":1376,"interventions":1377},[60],[1299],[1278,1301,1302,1303,1304,1305],{"intervention":1305,"totalTrials":63,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1381,"activeCount":67},[],{"trials":1383,"activeCount":67},[],{"trials":1385,"activeCount":67},[],{"trials":1387,"activeCount":67},[],{"trials":1389,"activeCount":67},[],{"trials":1391,"activeCount":67},[1392],{"nctId":1293,"briefTitle":1294,"status":1267,"phases":1393,"start":1296,"enrollment":1297,"conditions":1394,"interventions":1395},[60],[1299],[1278,1301,1302,1303,1304,1305]]